Company

Protalix BioTherapeutics, Inc. (PLX)

Standardized SEC financial data for Protalix BioTherapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001006281 · NYSE · Biological Products, (No Diagnostic Substances).

Gross margin

48.8%

Operating margin

-10.4%

Net margin

-12.5%

Revenue growth (YoY)

-1.2%

Return on equity

-13.7%

ROIC

-12.6%

Free cash flow

-$13.6M

Debt / equity

0.02×

Ratios for fiscal year 2025, standardized from SEC filings.

Income statement

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$62.9M	$38.4M	$47.6M	$65.5M	$53.4M	$52.7M
Cost of revenue	$10.9M	$16.3M	$19.6M	$23.0M	$24.3M	$27.0M
Gross profit	$52.0M	$22.0M	$28.0M	$42.5M

Balance sheet

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$18.3M	$39.0M	$17.1M	$23.6M	$19.8M	$14.7M
Inventory	$13.1M	$18.0M	$16.8M	$19.0M	$21.2M	$25.7M
Total current assets	$55.7M	$61.7M	$44.9M	$69.9M

Cash flow

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$26.1M	-$10.3M	-$25.0M	-$1.3M	$8.7M	-$12.0M
Capital expenditures	$655K	$1.5M	$628K	$1.1M	$1.3M	$1.6M
Free cash flow	-$26.8M	-$11.7M	-$25.6M	-$2.5M

Get PLX data via API

# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/PLX/financials \
  -H "X-API-Key: YOUR_KEY"

# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/PLX/income-statement?format=csv" \
  -H "X-API-Key: YOUR_KEY"

Get a free API key Use with Claude (MCP) →View PLX filings on SEC EDGAR →